07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Tenofovir alafenamide fumarate: Phase III data

Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.   Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine)   Business: Infectious   Molecular target: NA   Description: Co-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir, a...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Clinical News

Atazanavir/ritonavir regulatory update

FDA granted tentative marketing approval to an NDA from Mylan's Mylan Laboratories Ltd. subsidiary for a fixed-dose atazanavir/ritonavir combination to treat HIV/AIDS infection. The product will be eligible for purchase outside the U.S. under the...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Company News

Mylan, Pfizer, William J. Clinton Foundation infectious news

The foundation's HIV/AIDS Initiative announced agreements with Mylan and Pfizer to offer more affordable treatments for patients in the developing world with drug-resistant HIV. Pfizer agreed to sell generic rifabutin to treat tuberculosis (TB) in...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

Viramune nevirapine: Phase IIIb data

Data from the open-label, international Phase IIIb ARTEN trial in 569 treatment-naïve HIV patients showed that once- or twice-daily Viramune plus Truvada emtricitabine/tenofovir met the primary endpoint of non-inferiority to once-daily Reyataz atazanavir/...
07:00 , Aug 11, 2008 |  BC Week In Review  |  Clinical News

Atazanavir: Phase III data

In the open-label, international Phase III CASTLE study in 883 antiretroviral-naïve patients with HIV-1, once-daily atazanavir/ritonavir was non-inferior to twice-daily Kaletra lopinavir/ritonavir on the primary endpoint. Specifically, 78% of those receiving atazanavir/ritonavir and 76%...
07:00 , May 14, 2007 |  BC Week In Review  |  Clinical News

Viramune nevirapine: Phase IIIb started

The company began the open-label, international Phase IIIb ArTEN trial in 561 treatment-naïve HIV patients to compare once- or twice-daily Viramune plus tenofovir to once-daily atazanavir/ritonavir plus tenofovir. Viread tenofovir is marketed by ...